drugset / Trial / NCT01849692
ESBA1008 Microvolume Study
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).
Timeline
- Start
- 2013-06
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brolucizumab | Other / unclassified | 0.5 mg | Other |
| Subject | Brolucizumab | Other / unclassified | 0.6 mg | Other |
| Subject | Brolucizumab | Other / unclassified | 1 mg | Other |
| Subject | Brolucizumab | Other / unclassified | 1.2 mg | Other |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Other |